Compare Costco Wholesale Corporation (COST) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Viatris Inc — how do they compare? Costco Wholesale Corporation trades at $946.38 (market cap $418.79B), while Viatris Inc trades at $16.21 (market cap $18.69B). The key difference: Costco Wholesale Corporation is far larger — about 22.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| COST | VTRS | |
|---|---|---|
Market Cap | $418.79B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $17.86 |
52-Week Low | $849.63 | $9.49 |
Enterprise Value | $406.93B | $30.80B |
Dividend Yield | 0.62% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COST trades at $952.75, up 0.52% today, with a neutral technical signal. The stock shows strong fundamentals, including revenue growth to $275.24B in 2025 and consistent earnings beats, though Q1 2026 missed estimates. Positive sentiment is driven by a 65.52% analyst buy rating and a consensus price target of $1,120. Recent news highlights membership fee hikes and robust March sales, supporting investor confidence.
Outlook remains favorable due to steady growth and high institutional ownership, but risks include elevated valuation (P/E 47.5) and competitive pressures. The stock offers long-term potential if earnings momentum continues, though near-term volatility may persist amid market fluctuations.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
